{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T04:41:59Z","timestamp":1792125719257,"version":"4.4.0"},"update-to":[{"DOI":"10.1371\/journal.pntd.0011238","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T00:00:00Z","timestamp":1682985600000}}],"reference-count":44,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:00:00Z","timestamp":1681948800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Leprosy reactions (LRs) are inflammatory responses observed in 30%-50% of people with leprosy. First-line treatment is glucocorticoids (GCs), often administered at high doses with prolonged courses, resulting in high morbi-mortality. Methotrexate (MTX) is an immunomodulating agent used to treat inflammatory diseases and has an excellent safety profile and worldwide availability. In this study, we describe the efficacy, GCs-sparing effect and safety of MTX in LRs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective multicentric study in France consisting of leprosy patients receiving MTX for a reversal reaction (RR) and\/or erythema nodosum leprosum (ENL) since 2016. The primary endpoint was the rate of good response (GR) defined as the complete disappearance of inflammatory cutaneous or neurological symptoms without recurrence during MTX treatment. The secondary endpoint was the GCs-sparing effect, safety and clinical relapse after MTX discontinuation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our study included 13 patients with LRs (8 men, 5 women): 6 had ENL and 7 had RR. All patients had had at least one previous course of GCs and 2 previous treatment lines before starting MTX. Overall, 8\/13 (61.5%) patients had GR, allowing for GCs-sparing and even GCs withdrawal in 6\/11 (54.5%). No severe adverse effects were observed. Relapse after MTX discontinuation was substantial (42%): the median relapse time was 5.5 months (range 3\u201314) after stopping treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>MTX seems to be an effective alternative treatment in LRs, allowing for GCs-sparing with a good safety profile. Furthermore, early introduction during LRs may lead to a better therapeutic response. However, its efficacy seems to suggest prolonged therapy to prevent recurrence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pntd.0011238","type":"journal-article","created":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T14:44:17Z","timestamp":1682001857000},"page":"e0011238","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":17,"title":["Methotrexate as a corticosteroid-sparing agent in leprosy reactions: A French multicenter retrospective study"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1968-0275","authenticated-orcid":true,"given":"L\u00e9a","family":"Jaume","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estelle","family":"Hau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gentiane","family":"Monsel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Mah\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Bertolotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Petit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britney","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Chauveau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Duhamel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Maisonobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Bagot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-David","family":"Bouaziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fa\u00efza","family":"Mougari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Cambau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Jachiet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Groupe d\u2019infectiologie en dermatologie et des infections sexuellement transmissibles (GrIDIST)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,4,20]]},"reference":[{"issue":"1","key":"pntd.0011238.ref001","first-page":"14","article-title":"Leprosy: Clinical aspects and diagnostic techniques","volume":"83","author":"MBC Maymone","year":"2020","journal-title":"J AM ACAD DERMATOL"},{"issue":"2","key":"pntd.0011238.ref002","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1128\/CMR.19.2.338-381.2006","article-title":"The continuing challenges of leprosy","volume":"19","author":"DM Scollard","year":"2006","journal-title":"Clin Microbiol Rev. avr"},{"issue":"4","key":"pntd.0011238.ref003","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jaad.2014.03.034","article-title":"Recognizing and managing the immunologic reactions in leprosy","volume":"71","author":"S Kamath","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"pntd.0011238.ref004","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1136\/jcp.2007.053389","article-title":"The histological diagnosis of leprosy type 1 reactions: identification of key variables and an analysis of the process of histological diagnosis","volume":"61","author":"DNJ Lockwood","year":"2008","journal-title":"J Clin Pathol"},{"issue":"1","key":"pntd.0011238.ref005","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s40249-016-0229-3","article-title":"The influence of innate and adaptative immune responses on the differential clinical outcomes of leprosy.","volume":"6","author":"L Fonseca AB de","year":"2017","journal-title":"Infect Dis Poverty. 6 f\u00e9vr"},{"issue":"3","key":"pntd.0011238.ref006","doi-asserted-by":"crossref","first-page":"e2690","DOI":"10.1371\/journal.pntd.0002690","article-title":"The mortality associated with erythema nodosum leprosum in Ethiopia: a retrospective hospital-based study.","volume":"8","author":"SL Walker","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"pntd.0011238.ref007","doi-asserted-by":"crossref","first-page":"e0003431","DOI":"10.1371\/journal.pntd.0003431","article-title":"Household costs of leprosy reactions (ENL) in rural India.","volume":"9","author":"DJ Chandler","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0011238.ref008","volume":"22","author":"DNJ Lockwood","journal-title":"AZALEP a randomized controlled trial of azathioprine to treat leprosy nerve damage and Type 1 reactions in India: Main findings."},{"issue":"4","key":"pntd.0011238.ref009","doi-asserted-by":"crossref","first-page":"e0004502","DOI":"10.1371\/journal.pntd.0004502","article-title":"A Randomized Controlled Double Blind Trial of Ciclosporin versus Prednisolone in the Management of Leprosy Patients with New Type 1 Reaction, in Ethiopia.","volume":"10","author":"SM Lambert","year":"2016","journal-title":"PLoS Negl Trop Dis."},{"issue":"3","key":"pntd.0011238.ref010","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1440-0960.2009.00534.x","article-title":"Comparative efficacy of thalidomide and prednisolone in the treatment of moderate to severe erythema nodosum leprosum: a randomized study","volume":"50","author":"I Kaur","year":"2009","journal-title":"Australas J Dermatol. ao\u00fbt"},{"issue":"4","key":"pntd.0011238.ref011","doi-asserted-by":"crossref","first-page":"355","DOI":"10.47276\/lr.80.4.355","article-title":"Interventions for erythema nodosum leprosum. A Cochrane review.","volume":"80","author":"NHJ Van Veen","year":"2009","journal-title":"Lepr Rev. d\u00e9c"},{"issue":"3","key":"pntd.0011238.ref012","doi-asserted-by":"crossref","first-page":"213","DOI":"10.47276\/lr.82.3.213","article-title":"Does clofazimine prevent erythema nodosum leprosum (ENL) in leprosy? A retrospective study, comparing the experience of multibacillary patients receiving either 12 or 24 months WHO-MDT.","volume":"82","author":"M Balagon","year":"2011","journal-title":"Lepr Rev"},{"issue":"2","key":"pntd.0011238.ref013","doi-asserted-by":"crossref","first-page":"208","DOI":"10.47276\/lr.88.2.208","article-title":"A prospective randomised, double-blind, placebo controlled trial on the effect of extended clofazimine on Erythema Nodosum Leprosum (ENL) in multibacillary (MB) leprosy.","volume":"88","author":"A Maghanoy","year":"2017","journal-title":"Leprosy Review."},{"issue":"5","key":"pntd.0011238.ref014","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.4269\/ajtmh.19-0616","article-title":"Biologics in Leprosy: A Systematic Review and Case Report","volume":"102","author":"AL Cogen","year":"2020","journal-title":"Am J Trop Med Hyg"},{"key":"pntd.0011238.ref015","article-title":"Apremilast in multibacillary leprosy patients with chronic and recurrent erythema nodosum leprosum: A prospective single centre pilot study","author":"T Narang","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"pntd.0011238.ref016","first-page":"473","article-title":"Methotrexate in rheumatoid arthritis.","volume":"58","author":"J Swierkot","year":"2006","journal-title":"Pharmacol Rep. ao\u00fbt"},{"issue":"1","key":"pntd.0011238.ref017","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/bjd.14816","article-title":"British Association of Dermatologists\u2019 guidelines for the safe and effective prescribing of methotrexate for skin disease 2016","volume":"175","author":"RB Warren","year":"2016","journal-title":"British Journal of Dermatology"},{"key":"pntd.0011238.ref018","volume":"3","author":"G Biosca","journal-title":"Methotrexate Treatment for Type 1 (Reversal) Leprosy Reactions.:"},{"issue":"4","key":"pntd.0011238.ref019","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1489\/1544-581X(2004)72<480:MIRE>2.0.CO;2","article-title":"Methotrexate in resistant ENL.","volume":"72","author":"BR Kar","year":"2004","journal-title":"Int J Lepr Other Mycobact Dis"},{"issue":"4","key":"pntd.0011238.ref020","doi-asserted-by":"crossref","first-page":"379","DOI":"10.47276\/lr.86.4.379","article-title":"Effectiveness of Methotrexate in prednisolone and thalidomide resistant cases of Type 2 lepra reaction: report on three cases.","volume":"86","author":"R Nagar","year":"2015","journal-title":"LEPROSY."},{"key":"pntd.0011238.ref021","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.ijid.2020.12.024","article-title":"Severe type 2 leprosy reaction with COVID-19 with a favourable outcome despite continued use of corticosteroids and methotrexate and a hypothesis on the possible immunological consequences","volume":"103","author":"S Saxena","year":"2021","journal-title":"Int J Infect Dis"},{"issue":"1","key":"pntd.0011238.ref022","doi-asserted-by":"crossref","first-page":"118","DOI":"10.47276\/lr.87.1.118","article-title":"Management of chronic neuritis with a combination regimen of lower doses prednisolone and methotrexate: a brief report.","volume":"87","author":"D. Hossain","year":"2016","journal-title":"Leprosy Review."},{"issue":"1","key":"pntd.0011238.ref023","first-page":"105","article-title":"Using methotrexate to treat patients with ENL unresponsive to steroids and clofazimine: a report on 9 patients.","volume":"84","author":"D. Hossain","year":"2013","journal-title":"Lepr Rev."},{"issue":"4","key":"pntd.0011238.ref024","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/JD9.0000000000000133","article-title":"Efficacy and Safety of Prednisolone Monotherapy Versus Prednisolone Plus Methotrexate in Erythema Nodosum Leprosum (Type 2 Lepra Reaction).","volume":"3","author":"Z Hasan","year":"2020","journal-title":"International Journal of Dermatology and Venereology"},{"key":"pntd.0011238.ref025","doi-asserted-by":"crossref","first-page":"101670","DOI":"10.1016\/j.tmaid.2020.101670","article-title":"Use of methotrexate for leprosy reactions. Experience of a referral center and systematic review of the literature.","volume":"37","author":"JA Perez-Molina","year":"2020","journal-title":"Travel Med Infect Dis"},{"key":"pntd.0011238.ref026","unstructured":"WHO-MVP-EMP-IAU-2019.06-eng.pdf [Internet]. [cit\u00e9 29 ao\u00fbt 2021]. Disponible sur: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/325771\/WHO-MVP-EMP-IAU-2019.06-eng.pdf"},{"issue":"4","key":"pntd.0011238.ref027","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jbspin.2006.01.007","article-title":"Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion.","volume":"73","author":"S Pavy","year":"2006","journal-title":"Joint Bone Spine. juill"},{"issue":"5","key":"pntd.0011238.ref028","first-page":"197","article-title":"Folate Supplementation for Methotrexate Therapy in Patients With Rheumatoid Arthritis: A Systematic Review.","volume":"25","author":"L Liu","year":"2019","journal-title":"JCR: Journal of Clinical Rheumatology."},{"issue":"3","key":"pntd.0011238.ref029","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s12325-016-0295-8","article-title":"Methotrexate and Rheumatoid Arthritis: Current Evidence Regarding Subcutaneous Versus Oral Routes of Administration.","volume":"33","author":"G Bianchi","year":"2016","journal-title":"Adv Ther."},{"issue":"5","key":"pntd.0011238.ref030","doi-asserted-by":"crossref","first-page":"e13051","DOI":"10.1111\/dth.13051","article-title":"Subcutaneous methotrexate versus oral form for the treatment and prophylaxis of chronic plaque psoriasis.","volume":"32","author":"EM Attwa","year":"2019","journal-title":"Dermatol Ther"},{"key":"pntd.0011238.ref031","first-page":"58","volume-title":"Leprosy hansen disease: management of reactions and prevention of disabilities: technical guidance [Internet].","author":"World Health Organization","year":"2020"},{"issue":"1","key":"pntd.0011238.ref032","doi-asserted-by":"crossref","first-page":"25","DOI":"10.47276\/lr.77.1.25","article-title":"Multi-centre, double blind, randomized trial of three steroid regimens in the treatment of type-1 reactions in leprosy.","volume":"77","author":"Sugamaran DST Rao PSSS","year":"2006","journal-title":"Lepr Rev."},{"issue":"5","key":"pntd.0011238.ref033","first-page":"CD005491","article-title":"Corticosteroids for treating nerve damage in leprosy.","author":"NHJ Van Veen","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"pntd.0011238.ref034","doi-asserted-by":"crossref","first-page":"e0005952","DOI":"10.1371\/journal.pntd.0005952","article-title":"Effectiveness of 32 versus 20 weeks of prednisolone in leprosy patients with recent nerve function impairment: A randomized controlled trial.","volume":"11","author":"I Wagenaar","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"issue":"10","key":"pntd.0011238.ref035","doi-asserted-by":"crossref","first-page":"e0006011","DOI":"10.1371\/journal.pntd.0006011","article-title":"Clinico-pathological features of erythema nodosum leprosum: A case-control study at ALERT hospital, Ethiopia.","volume":"11","author":"E Negera","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"issue":"3","key":"pntd.0011238.ref036","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1191\/096120301676669495","article-title":"Azathioprine therapy for patients with systemic lupus erythematosus","volume":"10","author":"M Abu-Shakra","year":"2001","journal-title":"Lupus"},{"issue":"2","key":"pntd.0011238.ref037","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1590\/S0365-05962013000200003","article-title":"Adverse effects of alternative therapy (minocycline, ofloxacin, and clofazimine) in multibacillary leprosy patients in a recognized health care unit in Manaus, Amazonas, Brazil.","volume":"88","author":"MV Maia","year":"2013","journal-title":"An Bras Dermatol"},{"issue":"12","key":"pntd.0011238.ref038","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1212\/01.WNL.0000037480.59194.85","article-title":"Thalidomide-induced neuropathy.","volume":"59","author":"V Chaudhry","year":"2002","journal-title":"Neurology"},{"issue":"7224","key":"pntd.0011238.ref039","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(62)91248-5","article-title":"Thalidomide and congenital abnormalities","volume":"1","author":"AL Speirs","year":"1962","journal-title":"Lancet"},{"issue":"4","key":"pntd.0011238.ref040","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1111\/bjd.18233","article-title":"Apremilast in chronic recalcitrant erythema nodosum leprosum: a report of two cases","volume":"182","author":"T Narang","year":"2020","journal-title":"Br J Dermatol"},{"issue":"2","key":"pntd.0011238.ref041","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1590\/S0100-879X2007000200011","article-title":"Double-blind trial of the efficacy of pentoxifylline vs thalidomide for the treatment of type II reaction in leprosy","volume":"40","author":"AM Sales","year":"2007","journal-title":"Braz J Med Biol Res"},{"issue":"3","key":"pntd.0011238.ref042","doi-asserted-by":"crossref","first-page":"e15258","DOI":"10.1111\/dth.15258","article-title":"Successful treatment of erythema nodosum leprosum with apremilast.","volume":"35","author":"C Abril-P\u00e9rez","year":"2022","journal-title":"Dermatol Ther."},{"issue":"2","key":"pntd.0011238.ref043","first-page":"e74","article-title":"Erythema nodosum leprosum successfully treated with apremilast: more effective and safer than classic treatments?","volume":"60","author":"EM S\u00e1nchez-Mart\u00ednez","year":"2021","journal-title":"Int J Dermatol. f\u00e9vr"},{"key":"pntd.0011238.ref044","unstructured":"London School of Hygiene and Tropical Medicine. Methotrexate and Prednisolone Study in Erythema Nodosum Leprosum (MaPS in ENL [Internet]. clinicaltrials.gov; 2021 f\u00e9vr [cit\u00e9 23 ao\u00fbt 2021]. Report No.: NCT03775460. Disponible sur: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03775460"}],"updated-by":[{"DOI":"10.1371\/journal.pntd.0011238","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T00:00:00Z","timestamp":1682985600000}}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0011238","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T14:39:48Z","timestamp":1683038388000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0011238"}},"subtitle":[],"editor":[{"given":"Husain","family":"Poonawala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,4,20]]},"references-count":44,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0011238","relation":{},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,20]]}}}